Showing results (21-30 of 35) with videos related to
Sort By:
Pageof 4
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 28, 2025
Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis studySofie S Detlefsen, Ditte S Andersen, Anja Ø Knudsen, et al.European Journal of Cancer (Oxford, England : 1990)|March 22, 2024
Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanomaRikke B Holmstroem, Sidsel Pedersen, Rebecca Jurlander, et al.The Lancet. Oncology|March 9, 2016
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trialChristina H Ruhlmann, Thomas Broe Christensen, Line Hammer Dohn, et al.European Journal of Cancer (Oxford, England : 1990)|October 15, 2024
Immune-related adverse events in a nationwide cohort of real-world melanoma patients treated with adjuvant anti-PD1 - Seasonal variation and association with outcomeRebecca Schou Jurlander, Louise Mahncke Guldbrandt, Rikke B Holmstroem, et al.International Journal of Cancer|April 29, 2026
Real-World Outcomes of Nivolumab and Ipilimumab in Metastatic Melanoma as Third Line and BeyondYago Garitaonaindia, Søren Kjær Petersen, Louise M Guldbrandt, et al.Acta Oncologica (Stockholm, Sweden)|January 16, 2023
Quality of life and mental health in real-world patients with resected stage III/IV melanoma receiving adjuvant immunotherapySidsel Pedersen, Rikke B Holmstroem, Annika von Heymann, et al.Journal of the National Cancer Institute|June 17, 2026
Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanomaYago Garitaonaindia, Adam A Luczak, Christina H Ruhlmann, et al.Cancers|November 13, 2021
Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data StudyMorten Fink, Anders Schwartz Vittrup, Lars Bastholt, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|May 2, 2026
Prevalence of antibody drug conjugated-induced nausea and vomiting (ADCINV) in patients with cancerRonald Chow, Daniel Zhang, Samy Kannout, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 10, 2024
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort studyStine K Christensen, Mette L Winther, Ida J Laursen, et al.Pageof 4